Respiratory Antiviral Treatment Market – Scope of the Report
TMR’s report on the global respiratory antiviral treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory antiviral treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global respiratory antiviral treatment market from 2020 to 2030.
The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the respiratory antiviral treatment market.
Request Brochure for Report –
Healthcare Providers Adopting Optimal Control Strategies to Overcome Issue of Drug Resistance
The respiratory antiviral treatment market is expected to surpass revenue of US$ 5.3 Bn by the end of 2030. However, the issue of antiviral resistance is emerging as a restraint for market growth. For instance, M2 ion-channel inhibitors and neuraminidase (NA) inhibitors are approved treatments for influenza; however, they are associated with drug resistance in individuals. As such, neuraminidase inhibitors are being used on an extensive scale as an anti-influenza drug, since this treatment is less susceptible to drug resistance.
Since drug resistance has led to increased cost of patient healthcare, companies in the respiratory antiviral treatment market are shifting their business models toward the development of vaccines to curb the spread of respiratory illnesses. Since coinfection of pneumonia and influenza has led to increased morbidity and mortality, healthcare providers are adopting optimal control strategies.
Request for Analysis of COVID19 Impact Respiratory Antiviral Treatment Product Market
Healthcare Facilities Increase Influenza and COVID-19 Testing Due to Ongoing Flu Season
The coronavirus (COVID-19) outbreak has sparked concern among individuals suffering from influenza. Due to similarities in symptoms, healthcare institutes are increasing awareness about the differences in symptoms. Though influenza and COVID-19 are both contagious respiratory illnesses, they are caused by different viruses. This confusion has created revenue opportunities for companies in the respiratory antiviral treatment market, since infected individuals are seeking professional help from doctors to identify the symptoms.
Influenza is a serious medical issue in western countries. A second wave of COVID-19 in European countries is likely to compromise healthcare facilities. Hence, healthcare professionals are identifying people at high risk of acquiring influenza and COVID-19, and are recommending preventive measures to minimize the pressure in healthcare facilities.
These factors are likely to drive the respiratory antiviral treatment market.
Global Respiratory Antiviral Treatment Market – Key Companies
- The respiratory antiviral treatment market report concludes with the company profiles section, which includes key information about major players in the global respiratory antiviral treatment market
- Leading players analyzed in the respiratory antiviral treatment market report include
- Hoffmann-La Roche Ltd.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Mylan Inc.
- Merck & Co., Inc.
- AstraZeneca plc.
- Each of these players has been profiled in the respiratory antiviral treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Buy Respiratory Antiviral Treatment Market Report –
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453